Snowden Capital Advisors LLC raised its holdings in Perrigo Company plc (NYSE:PRGO – Free Report) by 3.6% during the fourth quarter, Holdings Channel reports. The institutional investor owned 24,337 shares of the company’s stock after buying an additional 842 shares during the quarter. Snowden Capital Advisors LLC’s holdings in Perrigo were worth $626,000 as of its most recent SEC filing.
A number of other large investors have also recently made changes to their positions in PRGO. Barclays PLC lifted its position in shares of Perrigo by 44.8% during the third quarter. Barclays PLC now owns 120,502 shares of the company’s stock valued at $3,160,000 after purchasing an additional 37,268 shares in the last quarter. Nisa Investment Advisors LLC lifted its position in shares of Perrigo by 10.4% during the fourth quarter. Nisa Investment Advisors LLC now owns 304,948 shares of the company’s stock valued at $7,840,000 after purchasing an additional 28,843 shares in the last quarter. SG Americas Securities LLC bought a new position in shares of Perrigo during the fourth quarter valued at about $691,000. Janney Montgomery Scott LLC lifted its position in shares of Perrigo by 39.1% during the fourth quarter. Janney Montgomery Scott LLC now owns 90,624 shares of the company’s stock valued at $2,330,000 after purchasing an additional 25,472 shares in the last quarter. Finally, Sound Income Strategies LLC lifted its position in shares of Perrigo by 28.6% during the fourth quarter. Sound Income Strategies LLC now owns 482,811 shares of the company’s stock valued at $12,413,000 after purchasing an additional 107,427 shares in the last quarter. 95.91% of the stock is owned by institutional investors.
Perrigo Price Performance
PRGO opened at $27.42 on Wednesday. The firm has a 50-day moving average price of $26.26 and a 200-day moving average price of $26.17. The company has a market capitalization of $3.77 billion, a price-to-earnings ratio of -23.44 and a beta of 0.45. Perrigo Company plc has a twelve month low of $23.14 and a twelve month high of $30.93. The company has a quick ratio of 1.77, a current ratio of 2.56 and a debt-to-equity ratio of 0.94.
Perrigo Dividend Announcement
The business also recently announced a quarterly dividend, which will be paid on Tuesday, June 17th. Shareholders of record on Friday, May 30th will be given a dividend of $0.29 per share. The ex-dividend date is Friday, May 30th. This represents a $1.16 annualized dividend and a yield of 4.23%. Perrigo’s payout ratio is presently -88.55%.
Analysts Set New Price Targets
Separately, StockNews.com lowered shares of Perrigo from a “buy” rating to a “hold” rating in a research report on Wednesday, February 19th. Four equities research analysts have rated the stock with a hold rating and one has given a buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $33.00.
Check Out Our Latest Analysis on PRGO
Insider Buying and Selling at Perrigo
In other news, EVP Ronald Craig Janish sold 7,800 shares of the business’s stock in a transaction that occurred on Monday, March 10th. The shares were sold at an average price of $27.44, for a total value of $214,032.00. Following the completion of the sale, the executive vice president now directly owns 33,666 shares in the company, valued at approximately $923,795.04. The trade was a 18.81% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. 0.70% of the stock is currently owned by company insiders.
Perrigo Profile
Perrigo Company plc provides over-the-counter health and wellness solutions to enhance individual well-being in the United States, Europe, and internationally. It operates through Consumer Self-Care Americas and Consumer Self-Care International segments. The company develops, manufactures, markets, and distributes self-care consumer products, such as upper respiratory products, including cough suppressants, expectorants, and sinus and allergy relief; nutrition products consisting of infant formulas and nutritional beverages; digestive health products, including antacids, anti-diarrheal, and anti-heartburn; pain and sleep-aids products comprising pain relievers and fever reducers; and oral care products, which include toothbrushes, toothbrush replacement heads, floss, flossers, whitening products, and toothbrush covers.
See Also
- Five stocks we like better than Perrigo
- Conference Calls and Individual Investors
- Top 5 Stocks Hedge Funds Are Buying Right Now
- Growth Stocks: What They Are, What They Are Not
- Viking Holdings Posts Strong Q1, Eyes Growth Ahead
- Consumer Staples Stocks, Explained
- 2 Reasons Netflix’s 40% Rally Is Far From Over
Want to see what other hedge funds are holding PRGO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Perrigo Company plc (NYSE:PRGO – Free Report).
Receive News & Ratings for Perrigo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Perrigo and related companies with MarketBeat.com's FREE daily email newsletter.